İmplantabl Kardiyoverter-Defibrilatör Takılan Hastalarda Şok Tedavisinin Hasta Sağlık İlişkili Yaşam Kalitesine Etkisi
GİRİŞ ve AMAÇ: İmplantabl kardiyoverterdefibrilatörler (İKD' ler) ani kardiyak ölümün önüne geçerek, mortaliteyi etkin bir şekilde azaltmaktadır. Bununla birlikte, uygun ya da uygunsuz, İKD şoklaması, özellikle aşılması zor psikolojik süreçlere yol açar ve de kötü yaşam kalitesi ile ilişkilidir. Çalışmamızda, şoklama ile sağlık ilişkili yaşam kalitesi arasındaki ilişkiyi göstermeyi amaçladık. YÖNTEM ve GEREÇLER: Tek, iki ya da üç odacıklı (Kardiyak resenkronizasyon tedavisi-defibrilatör (KRTD) ) İKD implante edilmiş hastalar dahil edildi. Kliniğimize rutin cihaz kontrolü için başvuran hastalar, başvuruda ve 12. ayda Kısa Form-36 sağlık anketini tamamladılar. Klinik parametreler ve cihaz ölçümleri kayıt altına alındı. BULGULAR: Yaş ortalaması 62±12 olan, 161'i (74%) erkek toplam 217 hasta çalışmaya dahil edildi. Takiplerde ölüm gerçekleşen 10 (4.6%) hasta çalışma dışına alındı. Kalan 207 hastanın yaş ortalaması 62±12 idi. Takiplerde 26 (12.6%) hasta şoklama tedavisi aldı. 16 hasta uygun; 10 hasta is uygunsuz şok tedavisi aldı. 18 hastada 2 ya da daha fazla şok tedavisi saptandı. Sağlık durumu parametreleri, şoklama tedavisi gören hastalarda daha kötü saptandı. TARTIŞMA ve SONUÇ: İKD şoklama tedavisi, kötüleşmiş hasta yaşam kalitesi ile ilişkilidir. Dolayısıyla, rutin psikolojik durum değerlendirmesi, İKD hastalarının klinik takiplerine dahil edilmelidir.
The Effect of Shock Therapies on Health-Related Quality of Life in Patients with Implantable Cardioverter-Defibrrillator
INTRODUCTION: Implantable cardioverterdefibrillators (ICDs) reduce mortality from suddencardiac death (SCD) effectively. However, ICDdischarge, whether appropriate or inappropriate,represents a particularly challenging psychologicalevent and is associated with poor quality of life (QoL).We aimed to investigate the association of shock and thehealth-related QoL.METHODS: Patients implanted with either single, dualchamber ICDs or CRT-D devices were included. Whenthey presented at our clinic for regular device follow-up,they completed the Short-Form Health Survey 36 (SF-36) at baseline and 12 months. Clinical parameters anddevice measurements were recorded.RESULTS: A total of 217 patients, including 161 (74%)males with a mean age of 62±12 years, were included inthe study. We excluded 10 (4.6%) patients that diedduring the follow-up. The mean age of the remaining207 patients (53 female and 154 male) was 62±12 years.During the follow-up, 26 (12.6%) patients experiencedshock therapy. Six-teen of them had appropriate and 10of them had inappropriate shocks. Two or more shockswere delivered in 18 (8.7%) patients. Health statuspatterns were poor in patients received shock therapiesduring follow-up period.DISCUSSION and CONCLUSION: ICD shocks wereassociated with impaired health- related QoL. So,routine consideration of psychosocial situation needs tobe integrated into the clinical care of ICD patients.
___
- 1. Greenberg H, Case RB, Moss AJ et al.
MADIT-II Investigators. Analysis of mortality
events in the Multicenter Automatic
DefibrillatorImplantation Trial (MADIT-II). J Am
Coll Cardiol 2004; 43: 1459-65.
- 2. Bristow MR, Saxon LA, Boehmer J et al.
Cardiac resynchronization therapy with or without
an implantable defibrillator in advanced chronic
heart failure. N Engl J Med 2004; 350: 2140-50.
- 3. Are implantable cardioverter-defibrillators or
drugsmore effective in prolonging life? The
Antiarrhythmics Versus Implantable
Defibrillators(AVID) Trial Executive Committee.
Am J Cardiol 1997; 79: 661-3.
- 4. Sears SF Jr, Todaro JF, Lewis TS et al.
Examining the psychosocial impact of
implantablecardioverter defibrillators: a
literaturereview. Clin Cardiol. 1999;22(7):481-489.
- 5. Mark DB, Anstrom KJ, Sun JL et al. Quality
of life with defibrillator therapy or amiodarone in
heart failure. N Engl J Med 2008; 359:999– 1008.
- 6. Schron EB, Exner DV, Yao Q et al. Quality
of life in the antiarrhythmics versus implantable
defibrillators trial: Impact of therapy and influence
of adverse symptoms and defibrillator shocks.
Circulation 2002; 105:589–594
- 7. Wathen MS, DeGroot PJ, Sweeney MO et al.
Prospective randomized multicenter trial of
empirical antitachycardia pacing versus shocks for
spontaneous rapid ventricular tachycardia in
patients with implantable cardioverterdefibrillators:
Pacing Fast Ventricular Tachycardia Reduces
Shock Therapies (PainFREE Rx II) trial results.
Circulation. 2004;110:2591-6.
- 8. Sears SF Jr, Conti JB. Quality of life and
psychological functioning of ICD patients. Heart
2002;87:488–93.
- 9. Matchett M, Sears SF, Hazelton G et al. The
implantable cardioverter defibrillator: its history,
current psychological impact and future. Expert
Rev Med Devices 2009;6:43–50.
- 10. Ware JE, Sherbourne CD. The MOS 36-item
Short Form Health Survey (SF-36). I. Conceptual
framework and item selection. Med Care 1992; 30:
473-483.
- 11. Koçyiğit H, Aydemir Ö, Ölmez N et al.
Form-36 (KF-36)'nın Türkçe Versiyonunun.
Güvenilirliği ve Geçerliliği. İlaç ve Tedavi Dergisi.
1999; 12: 102-106.
- 12. Crespo EM, Kim J, Selzman KA. The use of
implantable cardioverter defibrillators for the
prevention of sudden cardiac death: a review of the
evidence and implications. Am J Med Sci. 2005
May;329(5):238-46.
- 13. Irvine J, Dorian P, Baker B et al. Quality of
life in the Canadian Implantable Defibrillator Study
(CIDS). Am Heart J. 2002;144:282-9.
- 14. Piotrowicz K, Noyes K, Lyness JM et al.
Physical functioning and mental well-being in
association with health outcome in patients enrolled
in the Multicenter Automatic Defibrillator
Implantation Trial II. Eur Heart J. 2007
Mar;28(5):601-7. Epub 2007 Feb 12.
- 15. Kamphuis HC, de Leeuw JR et al.
Implantable cardioverter defibrillator recipients:
quality of life in recipients with and without ICD
shock delivery: a prospective study. Europace. 2003
Oct;5(4):381-9.
- 16. Volosin KJ, Exner DV, Wathen MS et al.
Combining shock reduction strategies to enhance
ICD therapy: A role for computer modeling. J
Cardiovasc Electrophyisol 2011; 22:280–289.
- 17. Wollmann CG, Lawo T, Kuhlkamp V et al.
Implantable defibrillators with enhanced detection
algorithms: Detection performance and safety
results from the painfree SST study. Pacing Clin
Electrophysiol 2014; 9:1198– 1209
- 18. Wilkoff BL, Williamson BD, Stern RS et al.
Strategic programming of detection and therapy
parameters in implantable cardioverterdefibrillators
reduces shocks in primary prevention
patients results from the PREPARE (Primary
Prevention Parameters Evaluation) study. J Am
Coll Cardiol 2008; 52:541–550.
- 19. Moss AJ, Schuger C, Beck CA et al.
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012;
367:2275– 2283.
- 20. Gasparini M, Proclemer A, Klersy C et al.
Effect of Long-detection interval vs
standarddetection interval for implantable
cardioverter-defibrillators on antitachycardia pacing
and shock delivery: The ADVANCE III
randomized clinical trial. JAMA 2013; 309:1903–
1911
- 21. Guedon-Moreau L, Lacroix D, Sadoul N et
al. A randomized study of remote follow-up of
implantable cardioverter defibrillators: Safety and
efficacy report of the ECOST trial. Eur Heart J
2013; 34:605–614.
- 22. Sears SF, Whited A, Volosin KJ. Enhancing
Patient Care by Estimation and Discussion of Risk
for ICD Shock. Pacing Clin Electrophysiol. 2015
Jan;38(1):1-7.